|Rapid Review Complete
|Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended
A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes.